Login Register Cart 0
Generic placeholder image

Coronaviruses

Editor-in-Chief

ISSN (Print): 2666-7967
ISSN (Online): 2666-7975

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Review Article

The Current Outbreak of COVID-19 with Reference to India

Author(s): Harshita Gupta*

Volume 2, Issue 4, 2021

Published on: 26 October, 2020

Page: [448 - 459] Pages: 12

DOI: 10.2174/2666796701999201026203911

Abstract

This review summarizes the outbreak of viruses causing the fatal disease, which is highly pathogenic and efficiently transmitted from human to human. This first began in Wuhan, China, and now turned into an epidemic situation worldwide. A novel coronavirus (2019-nCoV) or severe acute respiratory syndrome coronavirus(SARS-CoV)-2 belongs to β-coronavirus genera originated in bats due to highly identical genome which leads to bat coronavirus. This review highlights the study of Indian Council of Medical Research, India, which determined the detection of pathogenic coronavirus in two different species of Indian bats. Indian Council of Medical Research, India, has successfully isolated the COVID-19 virus strain which was the first step towards diagnosis and the development of vaccines in the country. The outbreaks of coronavirus received worldwide attention for overcoming the challenges faced during this current pandemic as there is no clinically approved antiviral drug or vaccine available yet. However, preventive measures and different treatments were taken to cope with this viral outbreak. In response to this global outbreak, this review tries to explain the Virology, Epidemiology and pathogenesis, and discusses the diagnosis and treatment strategies of COVID-19. This review emphasizes the current update of COVID-19.

Keywords: Novel coronavirus, severe acute respiratory syndromes, epidemiology, world health organization, convalescent plasma, virus research, diagnostic laboratory.

Graphical Abstract

[1]
World Health Organization. Rolling updates on coronavirus disease (COVID-19). Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen[Cited: 11th May 2020].
[2]
Gorbalenya AE, Baker SC, Baric RS, et al. Severe acute respiratory syndrome-related coronavirus: The species and its viruses – a statement of the coronavirus study group. bioRxiv 2020.
[http://dx.doi.org/10.1101/2020.02.07.937862 ]
[3]
Wit ED, Doremalen NV, Falzarano D, et al. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol 2016; 14: 523-34.
[4]
World Health Organization. International travel and health SARS(severe acute respiratory syndrome) Available from: https://www.who.int/ith/diseases/sars/en/ [Cited: 1 Jan 2012].
[5]
Memish ZA, Zumla AI. AI-Hakeem RF, et al. Family cluster of Middle East respiratory syndrome coronavirus infections. N Engl J Med 2013; 368(26): 2487-94.
[6]
World Health Organization. Middle East respiratory syndrome (MERS-CoV). Availabel from: https://www.who.int/emergencies/mers-cov/en/[Cited: 2 Aug 2019].
[7]
World Health Organization. Coronavirus disease (COVID-19) Pandemic. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019 [Cited: 31stAugust 2020].
[8]
World Health Organization. Global India Available from: https://who.sprinklr.com/region/searo/country/in[Cited: 31stAugust 2020].
[9]
Su S, Wong G, Shi W, et al. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol 2016; 24(6): 490-502.
[10]
Perlman S, Netland J. Coronaviruses post-SARS: update on replication and pathogenesis. Nat Rev Microbiol 2009; 7(6): 439-50.
[11]
Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020; 395: 1-10.
[http://dx.doi.org/10.1016/S0140-6736(20)30251-8]
[12]
Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol 2015; 1282: 1-23.
[13]
Masters PS. The molecular biology of coronaviruses. Adv Virus Res 2006; 66: 193-292.
[14]
Knoops K, Kikkert M, Worm SH, et al. SARS-coronavirus replication is supported by a reticulovesicular network of modified endoplasmic reticulum. PLOS Biol 2008; 6(9): 1957-74.
[15]
Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020; 579(7798): 270-3.
[16]
Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003; 426(6965): 450-4.
[17]
Ge XY, Li JL, Yang XL, et al. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature 2013; 503(7477): 535-8.
[18]
Chinese SARS Molecular Epidemiology Consortium. Chinese Molecular evolution of the SARS coronavirus during the course of the SARS epidemic in China. Science 2004; 303(5664): 1666-9.
[http://dx.doi.org/10.1126/science.1092002 ]
[19]
Raj VS, Mou H, Smits SL, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 2013; 495(7440): 251-4.
[http://dx.doi.org/10.1038/nature12005]] [PMID: 23486063]
[20]
Barlan A, Zhao J, Sarkar MK, et al. Receptor variation and susceptibility to Middle East respiratory syndrome coronavirus infection. J Virol 2014; 88(9): 4953-61.
[http://dx.doi.org/10.1128/JVI.00161-14]] [PMID: 24554656]
[21]
Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. J Adv Res 2020; 24: 91-8.
[http://dx.doi.org/10.1016/j.jare.2020.03.005]] [PMID: 32257431]
[22]
Acter T, Uddin N, Das J, Akhter A, Choudhury TR, Kim S. Evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as coronavirus disease 2019 (COVID-19) pandemic: A global health emergency. Sci Total Environ 2020; 730(138996)138996
[http://dx.doi.org/10.1016/j.scitotenv.2020.138996]] [PMID: 32371230]
[23]
Yadav PD, Shete-Aich A, Nyayanit DA, et al. Detection of coronaviruses in Pteropus & Rousettus species of bats from different States of India. Indian J Med Res 2020; 151(2 & 3): 226-35.
[PMID: 32317409]
[24]
Singhal T. A Review of coronavirus disease-2019 (COVID-19). Indian J Pediatr 2020; 87(4): 281-6.
[http://dx.doi.org/10.1007/s12098-020-03263-6]] [PMID: 32166607]
[25]
National Health Commission of People’s Republic of China. Prevent guideline of 2019-nCoV. 2020. Available from: http://en.nhc.gov.cn/2020-04/05/c_78815.htm
[26]
National Health Commission of People’s Republic of China. Pneumonia diagnosis and treatment of 2019-nCoV infection from Chinese NHC and CDC 2020. 2020. Available from: http://www.nhc.gov.cn/xcs/zhengcwj/202001/4294563ed35b43209b31739bd0785e67/files/7a9309111267475a99d4306962c8bf78.pdf
[27]
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395(10223): 497-506.
[http://dx.doi.org/10.1016/S0140-6736(20)30183-5]] [PMID: 31986264]
[28]
Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020; 323(11): 1061-9.
[http://dx.doi.org/10.1001/jama.2020.1585]] [PMID: 32031570]
[29]
Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395(10223): 507-13.
[http://dx.doi.org/10.1016/S0140-6736(20)30211-7]] [PMID: 32007143]
[30]
Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med 2020; 382(13): 1199-207.
[http://dx.doi.org/10.1056/NEJMoa2001316] [PMID: 31995857]
[31]
Kim JY, Choe PG, Oh Y, et al. The first case of 2019 novel coronavirus pneumonia imported into Korea from Wuhan, China: Implication for infection prevention and control measures. J Korean Med Sci 2020; 35(5)e61
[http://dx.doi.org/10.3346/jkms.2020.35.e61] [PMID: 32030925]
[32]
Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends 2020; 14(1): 69-71.
[http://dx.doi.org/10.5582/bst.2020.01020] [PMID: 31996494]
[33]
Nishiura H, Jung SM, Linton NM, et al. The extent of transmission of novel coronavirus in Wuhan, China. J Clin Med 2020; 9(2): 1-5.
[http://dx.doi.org/10.3390/jcm9020330] [PMID: 31991628]
[34]
Bassetti M, Vena A, Giacobbe DR. The novel Chinese coronavirus (2019-nCoV) infections: Challenges for fighting the storm. Eur J Clin Invest 2020; 50(3)e13209
[http://dx.doi.org/10.1111/eci.13209] [PMID: 32003000]
[35]
Novel Coronavirus (2019-nCoV).. Situation Report-22 2019. Available from: https://www. who.int/docs/default-source/coronaviruses/situation- reports/20200211- sitrep - 22- ncov.pdf?sfvrsn=6f80d
[36]
Chatterjee P, Nagi N, Agarwal A, et al. The 2019 novel coronavirus disease (COVID-19) pandemic: A review of the current evidence. Indian J Med Res 2020; 151(2 & 3): 147-59.
[http://dx.doi.org/10.4103/ijmr.IJMR_519_20] [PMID: 32362642]
[37]
Press Information Bureau. Press Release Details Available from: https://pib.gov.in/PressReleseDetail. aspx?PRID=1601095[Cited: 30th Jan 2020].
[38]
Worldometer. A review of coronavirus disease-2019 (COVID-19). Available from: https://www.worldometers.info/coronavirus/
[39]
Gupta N, Potdar V, Praharaj I, et al. Laboratory preparedness for SARS-CoV-2 testing in India: Harnessing a network of virus research & diagnostic laboratories. Indian J Med Res 2020; 151(2 & 3): 216-25.
[PMID: 32242875]
[40]
World Health Organization. Coronavirus Disease (COVID-19). Situation Reports Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/
[41]
World Health Organization. Coronavirus Disease (COVID-19). Situation Report-102. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200501-covid-19 sitrep.pdf?sfvrsn=742f4a18_2
[42]
PIB’S Daily Bulletin on COVID-19. Available from: https://pib.gov.in/PressReleasePage.aspx?PRID=1620101 [Cited: 1 May 2020].
[43]
Government of India. COVID-19 State wise Status. Available from: https://www.mygov.in/covid-19 [Cited: 29th August 2020].
[44]
World Health Organization. WHO Coronavirus Disease (COVID 19)-Dashboard. Available from: https://covid19.who.int/table
[45]
Singh PK. The research community must meet the coronavirus disease 2019 challenge. Indian J Med Res 2020; 151(2 & 3): 116-7.
[http://dx.doi.org/10.4103/ijmr.IJMR_2396_20] [PMID: 32270770]
[46]
World Health Organization. Coronavirus symptoms Available from: https://www.who.int/health-topics/coronavirus#tab=tab_3
[47]
Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal 2020; 10(2): 102-8.
[http://dx.doi.org/10.1016/j.jpha.2020.03.001] [PMID: 32282863]
[48]
Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA 2020; 323(18): 1843-4.
[http://dx.doi.org/10.1001/jama.2020.3786] [PMID: 32159775]
[49]
Zhang F, Abudayyeh OO, Gootenberg JS. A protocol for detection of COVID-19 using CRISPR diagnostics Available from: https://www.broadinstitute.org/files/publications/special/COVID-19%20detection%20(updated).pdf
[50]
Shen K, Yang Y, Wang T, et al. Diagnosis, treatment, and prevention of 2019 novel coronavirus infection in children: experts’ consensus statement. World J Pediatr 2020; 16(3): 223-31.
[http://dx.doi.org/10.1007/s12519-020-00343-7. ]
[51]
Pan Y, Guan H, Zhou S, et al. Initial CT findings and temporal changes in patients with the novel coronavirus pneumonia (2019-nCoV): a study of 63 patients in Wuhan, China. Eur Radiol 2020; 30(6): 3306-9.
[http://dx.doi.org/10.1007/s00330-020-06731-x] [PMID: 32055945]
[52]
World Health Organization. Laboratory testing for coronavirus disease (COVID-19) in suspected human cases: interim guidance. Available from: https://apps.who.int/iris/bitstream/handle/10665/331329/WHO-COVID-19-laboratory-2020.4-eng.pdf?sequence=1&isAllowed=y
[53]
Wu H-S, Chiu S-C, Tseng T-C, et al. Serologic and molecular biologic methods for SARS-associated coronavirus infection, Taiwan. Emerg Infect Dis 2004; 10(2): 304-10.
[http://dx.doi.org/10.3201/eid1002.030731] [PMID: 15030702]
[54]
Zhao J, Yuan Q, Wang H, et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis 2020; 71(16): 1-22.
[PMID: 32221519]
[55]
Indian Council of Medical Research. Indian Council of Medical Research (ICMR) & National Institute of Virology (NIV), Pune develops and validates the indigenous IgG ELISA test “COVID KAVACH ELISA” for antibody detection for COVID-19. Available from: https://www.icmr.gov.in/pdf/press_realease_files/ICMR_PressRelease_14052020.pdf
[56]
Liu Y, Zhang L, Wei W, et al. Colorimetric detection of influenza A virus using antibody-functionalized gold nanoparticles. Analyst (Lond) 2015; 140(12): 3989-95.
[http://dx.doi.org/10.1039/C5AN00407A] [PMID: 25899840]
[57]
ICMR. India is the 5th country globally to isolate the COVID-19 virus strain. Available from: https://www.icmr.gov.in/pdf/press_realease_files/Press_Release_ICMR_13March2020.pdf
[58]
Indian council of medical research department of health research. Guidance on the use of truenatTM beta CoV. Available from: https://main.icmr.nic.in/sites/default/files/upload_documents/Guidance_TrueNat_14042020.pdf
[59]
Indian council of medical research. In the fight against COVID-19, India scales a new peak in daily testing, achieves record 10 lakhs test per day. Available from: https://www.icmr.gov.in/pdf/press_realease_files/PR_ICMR_10Lakhs_Testing_per_Day22082020.pdf
[60]
Indian council of medical research. SARS-CoV-2 (COVID-19) Testing: status update. Available from: https://main.icmr.nic.in/sites/default/files/whats_new/ICMR_testing_update_06May2020_9AM_IST.pdf
[61]
Indian council of medical research. SARS-CoV-2 (COVID-19) testing status. Available from: https://www.icmr.gov.in/
[62]
Choudhary ML, Vipat V, Jadhav S, et al. Development of in vitro transcribed RNA as positive control for laboratory diagnosis of SARS-CoV-2 in India. Indian J Med Res 2020; 151(2 & 3): 251-4.
[PMID: 32242876]
[63]
World Health Organization. Advice on the use of masks in the community, during home care and in health care settings in the context of the novel coronavirus 2019. nCoV outbreak (Interimguidance). Available from: https://apps.who.int/iris/rest/bitstreams/1274280/retrieve
[64]
CDC. 2019 Novel coronavirus, Wuhan, China. 2020. Available from: https://www.cdc.gov/coronavirus/2019ncov/casesupdates/summary.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fsummary.html
[65]
World Health Organization. Advice for public. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public
[66]
Abd El-Aziz TM, Stockand JD. Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status. Infect Genet Evol 2020; 83104327
[http://dx.doi.org/10.1016/j.meegid.2020.104327] [PMID: 32320825]
[67]
Agostini ML, Andres EL, Sims AC, et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. MBio 2018; 9(2): 1-15.
[http://dx.doi.org/10.1128/mBio.00221-18] [PMID: 29511076]
[68]
Li H, Wang YM, Xu JY, Cao B. Potential antiviral therapeutics for 2019 novel coronavirus. Zhonghua Jie He He Hu Xi Za Zhi 2020; 43(3): 170-2.
[PMID: 32164080]
[69]
Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res 2013; 100(2): 446-54.
[http://dx.doi.org/10.1016/j.antiviral.2013.09.015] [PMID: 24084488]
[70]
Kumari P, Singh A, Ngasainao MR, et al. Potential diagnostics and therapeutic approaches in COVID-19. Clin Chim Acta 2020; 510: 488-97.
[http://dx.doi.org/10.1016/j.cca.2020.08.013] [PMID: 32795547]
[71]
Te HS, Randall G, Jensen DM. Mechanism of action of ribavirin in the treatment of chronic hepatitis C. Gastroenterol Hepatol (N Y) 2007; 3(3): 218-25.
[PMID: 21960835]
[72]
Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther 2020; 14(1): 58-60.
[http://dx.doi.org/10.5582/ddt.2020.01012] [PMID: 32147628]
[73]
Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J 2005; 2: 69.
[http://dx.doi.org/10.1186/1743-422X-2-69] [PMID: 16115318]
[74]
Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30(3): 269-71.
[http://dx.doi.org/10.1038/s41422-020-0282-0] [PMID: 32020029]
[75]
Oxford University. Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19 2020. Available from: https://www.ox.ac.uk/news/2020-06-16-low-cost-dexamethasone-reduces-death-one-third-hospitalised-patients-severe
[76]
World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID 2020. Available from: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---22-june-2020
[77]
Gielen V, Johnston SL, Edwards MR. Azithromycin induces anti-viral responses in bronchial epithelial cells. Eur Respir J 2010; 36(3): 646-54.
[http://dx.doi.org/10.1183/09031936.00095809] [PMID: 20150207]
[78]
Gautret P, Lagier J-C, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020; 56(1)105949
[http://dx.doi.org/10.1016/j.ijantimicag.2020.105949] [PMID: 32205204]
[79]
Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res 2020; 178104787
[http://dx.doi.org/10.1016/j.antiviral.2020.104787] [PMID: 32251768]
[80]
Fata-Hartley CL, Palmenberg AC. Dipyridamole reversibly inhibits mengovirus RNA replication. J Virol 2005; 79(17): 11062-70.
[http://dx.doi.org/10.1128/JVI.79.17.11062-11070.2005] [PMID: 16103157]
[81]
Gresele P, Momi S, Falcinelli E. Anti-platelet therapy: phosphodiesterase inhibitors. Br J Clin Pharmacol 2011; 72(4): 634-46.
[http://dx.doi.org/10.1111/j.1365-2125.2011.04034.x] [PMID: 21649691]
[82]
Liu X, Li Z, Liu S, et al. Therapeutic effects of dipyridamole on COVID-19 patients with coagulation dysfunction. medRxiv 2020.
[http://dx.doi.org/10.1101/2020.02.27.20027557]
[83]
Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis 2020; 20(4): 398-400.
[http://dx.doi.org/10.1016/S1473-3099(20)30141-9] [PMID: 32113510]
[84]
MacLennan S, Barbara JA. Risks and side effects of therapy with plasma and plasma fractions. Best Pract Res Clin Haematol 2006; 19(1): 169-89.
[http://dx.doi.org/10.1016/j.beha.2005.01.033] [PMID: 16377549]
[85]
The Hindu. ICMR gets nod for clinical trial of convalescent plasma for COVID-19 treatment 2020. Available from: https://www.thehindu.com/sci-tech/health/icmr-gets-nod-for-clinical-trial-of-convalescent-plasma-for-covid-19-treatment/article31372977.ece
[86]
Leng Z, Zhu R, Hou W, et al. Transplantation of ACE2− mesenchymal stem cells improve the outcome of patients with COVID-19 pneumonia. Aging Dis 2020; 11(2): 216-28.
[http://dx.doi.org/10.14336/AD.2020.0228] [PMID: 32257537]
[87]
Wikipedia. COVID-19 drug repurposing research. Available from: https://en.wikipedia.org/wiki/COVID-19_drug_repurposing_research
[88]
Ravishankar B, Shukla VJ. Indian systems of medicine: a brief profile. Afr J Tradit Complement Altern Med 2007; 4(3): 319-37.
[http://dx.doi.org/10.4314/ajtcam.v4i3.31226]] [PMID: 20161896]
[89]
Ayush.gov. Advisory from ministry of ayush for meeting the challenge arising out of spread of corona virus (covid-19) in India. Available from: https://www.ayush.gov.in/docs/125.pdf
[90]
Rege AA, Chowdhary AS. Evaluation of ocimum sanctum and tinospora cordifolia as probable hiv-protease inhibitors. Int J Pharm Sci Rev Res 2014; 25(1): 315-8.
[91]
Rege AA, Chowdhary AS. Evaluation of some medicinal plants as putative HIV protease inhibitors. Indian Drugs 2013; 50(6): 24-8.
[92]
Panche AN, Chandra S, Diwan AD. Multi-target b-protease inhibitors from Andrographis paniculata: in silico and in vitro studies. Plants (Basel) 2019; 8(7): 231.
[http://dx.doi.org/10.3390/plants8070231] [PMID: 31319560]
[93]
Liu YT, Chen HW, Lii CK, et al. A diterpenoid, 14-deoxy-11, 12-didehydroandrographolide, in Andrographis paniculata reduces steatohepatitis and liver injury in mice fed a high-fat and high cholesterol diet. Nutrients 2020; 12(2): 1-17.
[http://dx.doi.org/10.3390/nu12020523] [PMID: 32085637]
[94]
Liu Z, Xiao X, Wei X, et al. Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV-2. J Med Virol 2020; 92(6): 595-601.
[http://dx.doi.org/10.1002/jmv.25726] [PMID: 32100877]
[95]
Keyaerts E, Vijgen L, Pannecouque C, et al. Plant lectins are potent inhibitors of coronaviruses by interfering with two targets in the viral replication cycle. Antiviral Res 2007; 75(3): 179-87.
[http://dx.doi.org/10.1016/j.antiviral.2007.03.003] [PMID: 17428553]
[96]
Nourazarian SM, Nourazarian A, Majidinia M, Roshaniasl E. Effect of root extracts of medicinal herb Glycyrrhiza glabra on HSP90 gene expression and apoptosis in the HT-29 colon cancer cell line. Asian Pac J Cancer Prev 2015; 16(18): 8563-6.
[http://dx.doi.org/10.7314/APJCP.2015.16.18.8563] [PMID: 26745117]
[97]
Olivieri F, Prasad V, Valbonesi P, et al. A systemic antiviral resistance-inducing protein isolated from Clerodendrum inerme Gaertn. is a polynucleotide:adenosine glycosidase (ribosome-inactivating protein). FEBS Lett 1996; 396(2-3): 132-4.
[PMID: 8914973]
[98]
Hussain F, Jahan N, Rahman KU, Sultana B, Jamil S. Identification of hypotensive biofunctional compounds of Coriandrum sativum and evaluation of their angiotensin-converting enzyme (ACE) inhibition potential. Oxid Med Cell Longev 2018.20184643736
[PMID: 30581531]
[99]
Pang XF, Zhang LH, Bai F, et al. Attenuation of myocardial fibrosis with curcumin is mediated by modulating expression of angiotensin II AT1/AT2 receptors and ACE2 in rats. Drug Des Devel Ther 2015; 9: 6043-54.
[PMID: 26648693]
[100]
Li HY, Yang M, Li Z, Meng Z. Curcumin inhibits angiotensin II-induced inflammation and proliferation of rat vascular smooth muscle cells by elevating PPAR-γ activity and reducing oxidative stress. Int J Mol Med 2017; 39(5): 1307-16.
[PMID: 28339005]
[101]
Rachmawati H, Soraya IS, Kurniati NF, Rahma A. In vitro study on antihypertensive and antihypercholesterolemic effects of a curcumin nanoemulsion. Sci Pharm 2016; 84(1): 131-40.
[http://dx.doi.org/10.3797/scipharm.ISP.2015.05] [PMID: 27110504]
[102]
Straughn AR, Kakar SS. Withaferin A: a potential therapeutic agent against COVID-19 infection. J Ovarian Res 2020; 13(1): 79.
[http://dx.doi.org/10.1186/s13048-020-00684-x] [PMID: 32684166]
[103]
Yi L, Li Z, Yuan K, et al. Small molecules blocking the entry of severe acute respiratory syndrome coronavirus into host cells. J Virol 2004; 78(20): 11334-9.
[http://dx.doi.org/10.1128/JVI.78.20.11334-11339.2004] [PMID: 15452254]
[104]
Mirzaie A, Halaji M, Dehkordi FS, Ranjbar R, Noorbazargan H. A narrative literature review on traditional medicine options for treatment of corona virus disease 2019 (COVID-19). Complement Ther Clin Pract 2020; 40101214
[http://dx.doi.org/10.1016/j.ctcp.2020.101214] [PMID: 32891290]
[105]
Rudra S, Kalra A, Kumar A, Joe W. Utilization of alternative systems of medicine as health care services in India: Evidence on AYUSH care from NSS 2014. PLoS One 2017; 12(5)e0176916
[http://dx.doi.org/10.1371/journal.pone.0176916] [PMID: 28472197]
[106]
Indian Council of Medical Research. ICMR process to develop vaccine to fight Covid 19 pandemic as per globally accepted norms of fast tracking Available from: https://www.icmr.gov.in/pdf/press_realease_files/ICMR_Press_Release_04072020.pdf
[107]
World Health Organization. Draft Landscape of COVID-19 candidate vaccine Available from: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines

Rights & Permissions Print Cite
Article Metrics
11
1
© 2024 Bentham Science Publishers | Privacy Policy